FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to molecules that specifically bind OX40, a TNF receptor superfamily (TNFRSF) representative; it can be used in medicine for the treatment of neoplasms.
EFFECT: proposed polypeptide contains a set of VHH domains binding OX40, and it is capable of modulating immune cells in order to enhance tumor destruction.
17 cl, 14 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
MULTIVALENT AND MULTISPECIFIC HYBRID PROTEINS THAT BIND TO DR5 | 2016 |
|
RU2748620C2 |
CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) | 2017 |
|
RU2728964C2 |
PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
Authors
Dates
2022-05-30—Published
2017-01-11—Filed